Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: The differences in the expression and clinical correlation of CXCL10 were evaluated in breast cancer patients. ( A ) The role of CXCL10 in breast cancer was predicted with the CanerSEA database. ( B ) Differences in the expression of CXCL10 in different types of breast cancer were analyzed with the TIMER2.0 database. ( C ) Based on GEPIA2 breast cancer data, a volcano map was drawn with bioinformatics to determine the expression level of CXCL10. ( D ) The relationship between CXCL10 and the clinical prognosis of breast cancer patients was analyzed with the TIMER2.0 database. ( E ) The expression level of CXCL10 in adjacent and cancerous tissues was detected by immunohistochemistry. ( F ) The expression differences in different clinical stages were analyzed with the GEPIA2 database. (*** p < 0.001)

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Expressing, Immunohistochemistry

Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: The composition of cells in the breast cancer tissue microenvironment, interactions between cells, and differences in CXCL10 expression between breast cancer cells and T cells were analyzed with the single-cell sequencing data. ( A - B ) The composition of the main cells in the microenvironment of breast cancer tissue was analyzed with the NGDC database. ( C ) The interaction relationships between various types of cells were analyzed. ( D ) The CXCL10 expression levels were analyzed in various types of cells

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Expressing, Single Cell, Sequencing

Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: Correlation and differential expression analyses of CXCL10-interacting molecules were performed in BC. ( A ) CXCL10-interacting molecules were analyzed with the String database. ( B - E ) The correlations between CXCL10 and CCL13, CXCL6, PF4V1, and CXCL12 were analyzed with the GEPIA2 database. ( F - I ) Differences in the expression of CCL13, CXCL6, PF4V1 and CXCL12 in breast cancer were analyzed with the GEPIA2 database. ( J ) The differential expression of CXCL10 and CXCL12 in breast epithelial cells and breast cancer cells was detected by western blotting. (* p < 0.05)

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Quantitative Proteomics, Expressing, Western Blot

Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: The differences in the expression and clinical correlation of CXCL12 were evaluated in BC patients. ( A ) Differences in CXCL12 expression in different types of breast cancer were analyzed with the TIMER2.0 database. ( B ) Based on GEPIA2 breast cancer data, a volcano map was drawn by bioinformatics to determine the expression of CXCL12. ( C ) Differences in the expression of CXCL12 in different clinical stages were analyzed with the GEPIA2 database. ( D ) The relationship between CXCL12 and the prognosis of breast cancer patients was analyzed with the TIMER2.0 database. ( E - F ) The expression of CXCL12 in different types of cells was analyzed with single-cell sequencing from the NGDC database. ( G ) The expression level of CXCL10 in adjacent and cancerous tissues was detected by immunohistochemistry. (*** p < 0.001)

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Expressing, Single Cell, Sequencing, Immunohistochemistry

Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: The impact of CXCL12 on breast cancer and its correlation with CXCL10 were evaluated. ( A ) CXCL12 knockdown efficiency was detected by Q-PCR. ( B - C ) The impact of CXCL12 knockdown on cell invasion ability was detected by transwell assays. ( D - E ) The effect of CXCL12 knockdown on cell migration ability was detected by scratch assays. ( F ) The effect of CXCL12 knockdown on CXCL10 expression was detected by Q-PCR. ( G ) The effect of CXCL12 knockdown on CXCL10 secretion levels was detected by ELISA. (*** p < 0.001)

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Knockdown, Migration, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Clinical and Experimental Medicine

Article Title: CXCL12-mediated T cell infiltration drives breast cancer metastasis

doi: 10.1007/s10238-026-02126-2

Figure Lengend Snippet: Correlations between CXCL12 and CXCL10 and CD4 + T and CD8 + T cells in the inflammatory microenvironment of breast cancer patients were evaluated, and correlations with the clinical prognosis of breast cancer patients were evaluated. ( A ) The role of CXCL10 in breast cancer was predicted with the CanerSEA database. ( B ) The expression levels of CXCL10 and CXCL12 in different types of T lymphocytes were analyzed in different types of breast cancer with the TIMER2.0 database. ( C - F ) The clinical prognosis under different conditions was analyzed with the TIMER2.0 database. ( G ) CD4 + T cells and CD8 + T cells in breast cancer tissues were analyzed by immunofluorescence

Article Snippet: After 24 h of incubation, the culture supernatants were analyzed with a human CXCL10 ELISA kit (R&D Systems, QK266).

Techniques: Expressing, Immunofluorescence